Formulation, stability, and delivery of live attenuated vaccines for human use

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 16, Issue 1, 1999, Pages 1-83

  Burke, Carl J ^a   Hsu, Tsu An ^b   Volkin, David B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Delivery; Lyophilization; Review; Stability; Vaccine

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; THERA CYS; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE; YELLOW FEVER VACCINE;

BCG VACCINATION; DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; IMMUNE RESPONSE; IMMUNIZATION; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; PERTUSSIS; POLIOMYELITIS VIRUS; REVIEW; ROTAVIRUS; RUBELLA VIRUS; TETANUS; VACCINATION; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS;

BACTERIAL VACCINES; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG STABILITY; HUMANS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0032963287     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (436)

1. Henderson, D. A. and Fenner, F., Smallpox and vaccinia, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
2. Ada, G., Overview of vaccines, in Methods in Molecular Methods: Vaccine Protocols, Robinson, A., Farrar, G. H., and Wiblin, C. N., Eds., Totowa, NJ: Humana Press, 1996.
3. Plotkin, S. A. and Mortimer, E. A., Eds., Vaccines, 2nd ed., Philadelphia, PA: W. B. Saunders, 1994.
4. Mimms, C. A., Playfair, J. H. L., Roitt, I. M., Wakelin, D., and Williams, R., Medical Microbiology, St. Louis: Mosby Press, 1993.
5. Melnick, J. L., Virus vaccines: Principles and prospects, Bull. WHO, 67, 105, 1989.
6. Ward, J., Lieberman, J. M., and Cochi, S. L., Hœmophilus influenzae vaccines, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
7. Gupta, R. K., Rost, B. E., Relyveld, E., and Siber, G. R., Adjuvant properties of aluminum and calcium salts, in Vaccine Design: The Subunit and Adjuvant Approach, Powell, M. F. and Newman, M. J., Eds., New York: Plenum Press, 1995.
8. Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. A., DNA vaccines, Annu. Rev. Immunol., 15, 617, 1997.
9. Cryz, S. J., Live attenuated vaccines for human use, Curr. Opin. Biotech., 3, 298, 1992.
10. Robbins, F. C., Polio - Historical, in Vaccines, 2nd ed., Plotkin, S. A., and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994, 137.
11. Murdin, A. D., Barreto, L., and Plotkin, S., Inactivated poliovirus vaccine: Past and present experience, Vaccine, 14, 735, 1996.
12. Melnick, J. L., Live attenuated poliovirus vaccines, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
13. Salk, J., Drucker, J. A., and Malvy, D., Noninfectious poliovirus vaccine, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
14. Schlein, L., Hunting down the last of poliovirus, Science, 279, 168, 1998.
15. Kantele, A., Arvilommi, H., Kantele, J. M., Rintala. L., and Makela, P. H., Comparison of the human response to live oral, killed oral, or killed parenteral Salmonella typhi TY2lA vaccines, Microb. Pathog., 10, 117, 1991.
16. Mackett, M. and Williamson, J. D., Human Vaccines and Vaccination, Oxford: Bios Scientific, 1995.
17. Levine, M. M., Enteric infections, Lancet, 335, 958, 1990.
18. Cryz, S. J., Live attenuated bacterial vaccine vector systems, Vaccine, 14, 676, 1996.
19. Cryz, S. J., Experience with live attenuated and inactivated vaccine delivery systems in humans, Vaccine, 14, 683, 1996.
20. Sizemore, D. R., Branstrom, A. A., and Sadoff J. C., Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immuniziation, Science, 270, 299, 1995.
21. Sizemore, D. R., Branstrom, A. A., and Sadoff, J. C., Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization, Vaccine, 15, 804, 1997.
22. Verma, I. M. and Somia, N., Gene therapy: Promises, problems, and prospects, Nature, 389, 239, 1997.
23. Russell, S. J., Replicating vectors for cancer therapy: A question of strategy, Sem. Cancer Biol., 5, 437, 1994.
24. Haase, M., Stability testing requirements for vaccines: Draft guidelines of the international conference on harmonization, in New Approaches to Stabilization of Vaccine Potency, Brown, F., Ed., Basel: S. Karger, 1996.
25. Fenyves, A., Regulatory practices and problems with vaccine stability studies and establishment of shelflives, in New Approaches to Stabilization of Vaccine Potency, Brown, F., Ed., Basel: S. Karger, 1996.
26. Griffiths, E., Assuring the quality of vaccines, in Methods in Molecular Medicine: Vaccine Protocols, Robinson, A., Farrar, G., and Wiblin, C., Eds., Totowa, NJ: Humana Press, 1996.
27. Parkman, P. D. and Hardegree, M. C., Regulation and testing of vaccines, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
28. Peetermens, J. H., Development and quality assessment of vaccines, in Polypeptide and Protein Drugs, Hider, R. C. and Barlow, D., Eds, New York: Ellis Horwood, 1991.
29. Hilleman, M. R., Improving the heat stability of vaccines: Problems, needs, and approaches, Rev. Infec. Dis., 11, Suppl. 3, S613, 1989.
30. Zaffran, M., Vaccine transport and storage: Environmental challenges, in New Approaches to Stabilization of Vaccine Potency, Brown, F., Ed., Basel: S. Karger, 1996.
31. Lugosi, L. and Battersby, A., Transport and storage of vaccines in Hungary: The first cold chain monitor study in Europe, Bull. WHO, 68, 431, 1990.
32. Briggs, H. and Ilett, S., Weak link in vaccine cold chain, Br. Med. J., 306, 557, 1993.
33. Haworth, E. A., Boy, R., Stirzaker, L., Wilkes, S., and Battersby, A., Is the cold chain for vaccines maintained in general practice?, Br. Med. J., 307, 242, 1993.
34. Kendal, A. P., Snyder, R., and Garrison, P. J., Validation of cold chain procedures suitable for distribution of vaccines by public health programs in the USA, Vaccine, 15, 1459, 1997.
35. Aylward, B., Kane, M., Batson, A., and Scott, R. M., A framework for the evaluation of vaccines for use in the Expanded Programme on Immunization, Vaccine, 12, 1155-1159, 1994.
36. John, T. J., Vaccine stability in the context of vaccine delivery in a developing country: India, in New Approaches to Stabilization of Vaccine Potency, Brown, F., Ed., Basel: S. Karger, 1996.
37. Lloyd, J. S., Improving the cold chain for vaccines, WHO Chronicle, 31, 13, 1977.
38. Little, L., Current trends: Impact of the well-characterized regulatory program, BioPharm August, 8, 1997.
39. Volkin, D. B. and Middaugh, C. R., The effect of temperature on protein structure, in Stability of Protein Pharmaceuticals: Chemical and Physical Pathways of Protein Degradation, Ahern, T. J. and Manning, M., Eds., New York: Plenum Press, 1992.
40. Powell, M. F., Amphlett, G., Cacia, J., Callahan, W., Cannova-Davis, E., Chang, B., Cleland, J. L., Darrington, T., DeYoung, L., Dhingra, B., Everett, R., Foster, L., Frenz, J., Garcia, A., Gilitinan, D., Gitlin, G., Gombotz, W., Hageman, M., Harris, R., Heller, D., Herman, A., Hershenson, S., Hora, M., Ingram, R., Janes, S., Kamat, M., Kroon, D., Keck, R. G., Luedke, E., Maneri, L., March, C., McCrossin, L., Nguyen, T., Patel, S., Qi, H., Rohde, M., Rosenblatt, B., Sahakian, N., Shahrokh, Z., Shire, S., Stevenson, C., Stoney, K., Thompson, S., Tolman, G., Volkin, D., Wang, J. Y., Warne, N., and Watanabe, C., A compendium and hydropathy/flexibility analysis of common reactive sites in proteins: Reactivity at Asn, Asp, Gln and Met motifs in neutral pH solution, in Formulation, Characterization and Stability of Protein Drugs: Case Histories, Wang, Y. J. and Pearlman, R., Eds., New York: Plenum Press, 1996.
41. Volkin, D. B., Mach, H., and Middaugh, C. R., Degradative covalent reactions important to protein stability, in Protein Stability and Folding: Theory and Practice, Shirley, B. A., Ed., Totowa, NJ: Humana Press, 1995.
42. Cleland, J. L., Powell, M. F., and Shire, S. J., The development of stable protein formulations: A close look at protein aggregation, deamidation and oxidation, Crit. Rev. Ther. Drug Carrier Syst., 10, 307, 1993.
43. Volkin, D. B. and Middaugh, C. R., The characterization, stabilization, and formulation of acidic fibroblast growth factor, in Formulation, Characterization, and Stability of Protein Drugs: Case Histories, Wang, Y. J. and Pearlman, R., Eds., New York: Plenum Press, 1996.
44. Volkin, D. B., Sanyal, G., Burke, C. J., and Middaugh, C. R., Preformulation studies as an essential guide to formulation development and manufacture of protein pharmaceuticals, in Development and Manufacture of Protein Pharmaceuticals, Akers, M. and Nail, S., Eds., New York: Plenum Press, in press.
45. Wang, Y. J. and Pearlman, R., Eds., Stability and Characterization of Protein Drugs: Case Histories, New York: Plenum Press, 1993.
46. Wang, Y. J. and Pearlman, R., Eds., Formulation, Characterization, and Stability of Protein Drugs: Case Histories, New York: Plenum Press, 1996.
47. Cleland, J. L. and Langer, R., Eds., Formulation and Delivery of Proteins and Peptides, Washington DC: American Chemical Society, 1994.
48. Ahern, T. J. and Manning, M., Eds., Stability of Protein Pharmaceuticals: Chemical and Physical Pathways cf Protein Degradation, New York: Plenum Press, 1992.
49. Volkin, D. B. and Klibanov, A. M., Minimizing protein inactivation, in Protein Function: A Practical Approach, Creighton, T. E., Ed., Oxford: Oxford Press, 1989.
50. Lindahl, T., Instability and decay of the primary structure of DNA, Nature, 362, 709, 1993.
51. Middaugh, C. R., Evans, R. K., Montgomery, D. L., and Casimiro, D. R., Analysis of plasmid DNA from a pharmaceutical perspective, J. Pharm. Sci., 87, 130, 1997.
52. Randolph, T. W., Phase separation of excipients during lyophilization: Effects of protein stability, J. Pharm. Sci., 86, 1198, 1997.
53. Arakawa, T., Kita, Y., and Carpenter, J. F., Protein-solvent interactions in pharmaceutical formulations, Pharm. Res., 8, 285, 1991.
54. Timasheff, S. N. and Arakawa, T., Stabilization of protein structure by solvents, in Protein Structure: A Practical Approach, Creighton, T. E., Ed., Oxford: Oxford University Press, 1989.
55. Timasheff, S. N., Stabilization of protein structure by solvent additives, in Stability of Protein Pharmaceuticals: In Vivo Pathways of Degradation and Strategies for Protein Stabilization, Ahern, T. J. and Manning, M., Eds., New York: Plenum Press, 1992.
56. Hochachka, P. W. and Somero, G. N., Biochemical Adaptation, Princeton NJ: Princeton University Press, 1984.
57. Vieille, C., Burdette, D. S., and Zeikus, J. G., Thermozymes, in Biotechnology Annual Reviews, vol. 2, El-Gewely, R. M., Ed., Amsterdam: Elsevier, 1996.
58. Jaenicke, R., Protein structure and function at low temperatures, Philos. Trans. R. Soc. Lond. Biol. Sci., 326, 535, 1990.
59. Carpenter, J. F. and Hansen, T. N., Antifreeze protein modulates cell survival during cryopreservation: Mediation through the influence on ice crystal growth, Proc. Nat. Acad. Sci. USA, 89, 8953, 1992.
60. Santoro, M. M., Liu, Y., Khan, S. M. A., Hou, L. X., and Bolen, D. W., Increased thermostability of proteins in the presence of naturally occurring osmolytes, Biochemistry, 31, 5278, 1992.
61. Murata, N., Mohanty, P. S., Hayashi, H., and Papageorgiou, G. C., Glycinebetaine stabilizes the association of extrinsic proteins with the photosynthetic oxygen-evolving complex, FEBS Lett., 296, 187, 1992.
62. Winzor, C. L., Winzor, D. J., Paleg, L. G., Jones, G. P., and Naidu, B. P., Rationalization of the effects of compatible solutes on protein stability in terms of thermodynamic nonideality, Arch. Biochem. Biophys., 296, 102, 1992.
63. Zhou, Y. and Hall, C. K., Solute excluded-volume effects on the stability of globular proteins: A statistical thermodynamic theory, Biopolymers, 38, 273, 1995.
64. Hottiger, T., De Virgilio, C., Hall, M. N., Boller, T., and Wiemken, A., The role of trehalose synthesis for the aquisition of thermotolerance in yeast, Eur. J. Biochem., 219, 187, 1994.
65. Roser, B., Trehalose drying: A novel replacement for freeze-drying, BioPharm, September, 47, 1991.
66. Levine, H. and Slade, L., Another view of trehalose for drying and stabilizing biological molecules, BioPharm, May, 36, 1992.
67. Mathias, S. F., Franks, F., and Hatley, R. H. M., The stabilization of proteins by freeze-drying and by alternative methods, in Polypeptide and Protein Drugs: Production, Characterization, and Formulation, Hider, R. C. and Barlow, D., Eds., New York: Ellis Horwood, 1991.
68. Franks, F., Storage stability of proteins, in Protein Biotechnology, Franks, F., Ed., Totowa, NJ: Humana Press, 1993.
69. Carpenter, J. F. and Crowe, J. H., An infrared spectroscopic study of the interaction of carbohydrates with dried proteins, Biochemistry, 28, 3916, 1989.
70. Crowe, J. H., Crowe, L. M., Carpenter, J. F., and Aurell-Wistrom, C., Stabilization of dry phospholipid bilayers and proteins by sugars, Biochem. J., 242, 1, 1987.
71. Crowe, J. H., Crowe, L. M., and Carpenter, J. F., Preserving dry biomaterials: The water replacement hypothesis, Part 1, BioPharm, April, 28, 1993.
72. Tanaka, K., Takida, T., and Miyarma, K., Cryoprotective effect of saccharides on denaturation of catalase by freeze-drying, Chem. Pharm. Bull., 39, 1091, 1991.
73. Crowe, J. H., Crowe, L. M., and Carpenter, J. F., Preserving dry biomaterials: The water replacement hypothesis, Part 2, BioPharm, May, 40, 1993.
74. Belton, P. S. and Gil, A. M., IR and Raman spectroscopic studies of the interaction of trehalose with hen egg white lysozyme, Biopolymers, 34, 957, 1994.
75. Rupley, J. A., Gratton, E., and Careri, G., Water and globular proteins, Trends Biochem. Sci., 8, 18, 1983.
76. Franks, F., Freezing drying: From empiricism to predictability, Cryo. Lett., 11, 93, 1990.
77. Fox, K. C., Putting proteins under glass, Science, 267, 1923, 1995.
78. Williams, N. A. and Polli, G. P., The lyophilization of pharmaceuticals: A literature review, J. Paren. Sci. Technol., 38, 48, 1984.
79. Carpenter, J. F., Pikal, M. J., Chang, B. S., and Randolph, T. W., Rational design of stable lyophilized formulations: Some practical advice, Pharm. Res., 14, 969, 1997.
80. Adams, G. D. J., Lyophilization of vaccines, in Methods in Molecular Methods: Vaccine Protocols, Robinson, A., Farrar, G. H., and Wiblin, C. N., Eds., Totowa, NJ: Humana Press, 1996.
81. Adams, G. D. J., Freeze-drying of biological materials, Drying Tech., 9, 891, 1991.
82. Pikal, M. J., Freeze-drying of proteins, I. Process design, BioPharm, September, 18, 1990.
83. Pikal, M. J., Freeze-drying of proteins, II. Formulation selection, BioPharm, October, 26, 1990.
84. Pikal, M. J., Freeze-drying of proteins: Process, formulation, and stability, in Formulation and Delivery of Proteins and Peptides, Cleland, J. L. and Langer, R., Eds., Washington DC: American Chemical Society, 1994.
85. May, J. C., Ed., International Symposium on Biological Product Freeze-Drying and Formulation, Basel: Karger, 1991.
86. Cabasso, V. J. and Regamey, R. H., Eds., International Symposium on Freeze-Drying of Biological Products, Basel: Karger, 1976.
87. 2O,Arch. Biochem. Biophys., 81, 319, 1959.
88. Bock, P. E. and Frieden, C., Another look at the cold lability of enzymes, Trends Biol. Sci., 3, 100, 1978.
89. Chang, B. S., Kendrick, B. S., and Carpenter, J. F., Surface-induced denaturation of proteins during freezing and its inhibition by surfactants, J. Pharm. Sci., 85, 1325, 1996.
90. Peter, M., Freezing of living cells: Mechanisms and implications, J. Am. Physiol. Soc., 247, C125, 1984.
91. Pikal, M. J. and Shah, S., Moisture transfer from stopper to product and resulting stability implications, Dev. Biol. Stand., 74, 165, 1992.
92. Earle, J. P., Bennett, P. S., Larson, K. A., and Shaw, R., The effects of stopper drying on moisture levels of Hœmophilus influenza conjugate vaccine, Dev. Biol. Stand., 74, 203, 1991.
93. Shalaev, E. Y. and Zografi, G., How does residual water affect the solid-state degradation of drugs in the amorphous state?, J. Pharm. Sci., 85, 1137, 1996.
94. Carpenter, J. F., Prestrelski, S. J., and Arakawa, T., Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization: Enzyme activity and calorimetric studies, Arch. Biochem. Biophys., 303, 456, 1993.
95. Prestrelski, S. J., Tedeschi, N., Arakawa, T., and Carpenter, J. F., Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers, Biophys. J., 65, 661, 1993.
96. Prestrelski, S. J., Arakawa, T., and Carpenter, J. F., Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization: Structural studies using infrared spectroscopy, Arch. Biochem. Biophys., 303, 465, 1993.
97. Dong, A., Prestrelski, S. J., Allison, S. D., and Carpenter, J. F., Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation, J. Pharm. Sci., 84, 415, 1995.
98. Chan, H. K., Ongpipattanakul, B., and Au-Yeung, J., Aggregation of rhDNase occurred during the compression of KBr pellets used for FTIR spectroscopy,Pharm. Res., 13, 238, 1996.
99. Griebenow, K. and Klibanov, A. M., Lyophilization-induced reversible changes in the secondary structure of proteins, Proc. Nat. Acad. Sci. USA, 92, 10969, 1995.
100. Zhang, M. Z., Wen, J., Arakawa, T., and Prestrelski, S. J., A new strategy for enhancing the stability of lyophilized protein: The effect of the reconstitution medium on keratinocyte growth factor, Pharm. Res., 12, 1447, 1995.
101. Izutsu, K. I., Yoshioka, S., and Terao, T., Decreased protein-stabilizing effects of cryoprotectants due to crystallization, Pharm. Res., 10, 1232, 1993.
102. Izutsu, K. I., Yoshioka, S., and Kojima, S., Physical stability and protein stability of freeze-dried cakes during storage at elevated temperatures, Pharm. Res., 11, 995, 1994.
103. Hsu, C. C., Ward, C. A., Pearlman, R., Nguyen, H. M., Yeung, D. A., and Curley, J. G., Determining the optimum residual moisture in lyophilized protein pharmaceuticals, Dev. Biol. Stand., 74, 255, 1991.
104. Constantino, H. R., Langer, R., and Klibanov, A. M., Moisture-induced aggregation of lyophilized insulin, Pharm. Res., 11, 21, 1994.
105. Constantino, H. R., Langer, R., and Klibanov, A. M., Aggregation of a lyophilized pharmaceutical protein, recombinant human albumin: Effect of moisture and stabilization by excipients, Bio/Technology, 13, 493, 1995.
106. Hsu, C. C., Nguyen, H. M., Yeung, D. A., Brooks, D. A., Koe, G. S., Bewley, T. A., and Pearlman, R., Surface denaturation at solid-void interface: A possible pathway by which opalescent particulates form during storage of lyophilized tissue-type plasminogen activator at high temperatures, Pharm. Res., 12, 69, 1995.
107. Chang, B. S., Beauvais, R. M., Dong, A., and Carpenter, J. F., Physical factors affecting the storage stability of freeze-dried interleukin-1 receptor antagonist: Glass transition and protein conformation, Arch. Biochem. Biophys., 331, 249, 1996.
108. Hillery, A. M., Supramolecular lipidic drug delivery systems: From laboratory to clinic, A review of the recently introduced commercial liposomal and Lipid-based formulations of amphotericin B, Adv. Drug Del. Rev., 24, 345, 1997.
109. Ceh, B., Winterhalter, M., Frederik, P. M., Vallner, J. J., and Lasic, D. D., Stealth® liposomes: From theory to product, Adv. Drug Del. Rev., 24, 165, 1997.
110. Gluck, R., Mischler, R., Brantschen, S., Just, M., Althaus, B., and Cryz, S. J., Jr., Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A, J. Clin. Invest., 90, 2491, 1992.
111. Ambrosch, F., Wiedermann, G., Jonas, S., Althaus, B., Finkel, B., Gluck, R., and Herzog, C., Immunogenicity and protectivity of a new liposomal hepatitis A vaccine, Vaccine, 15, 1209, 1997.
112. Anchordoquy, T. J., Carpenter, J. F., and Kroll, D. J., Maintanence of transfection rates and physical characterization of lipid/DNA complexes after freeze-drying and rehydration, Arch. Biochem. Biophys., 34, 199, 1997.
113. Vemuri, S. and Rhodes, C. T., Preparation and characterization of liposomes as therapeutic delivery systems: A review, Pharm. Acta Helv., 70, 95, 1995.
114. Talsma, H. and Crommelin, D. J. A., Liposomes as drug delivery systems, I. Preparation, Pharm. Tech., October, 96, 1992.
115. Talsma, H. and Crommelin, D. J. A., Liposomes as drug delivery systems, II. Characterization, Pharm. Tech., November, 52, 1992.
116. Talsma, H. and Crommelin, D. J. A., Liposomes as drug delivery systems, III. Stabilization, Pharm. Tech., January, 48, 1993.
117. Crowe, J. H., Spargo, B. J., and Crowe, L. M., Preservation of dry liposomes does not require retention of residual water, Proc. Nat. Acad. Sci. USA, 84, 1537, 1987.
118. Crowe, J. M., Womersley, C., Crowe, L. H., Reid, D., Appel, L., and Rudolph, A., Prevention of fusion and leakage in freeze-dried liposomes by carbohydrates, Biocem. Biophys. Acta, 861, 131, 1986.
119. Sun, W. Q., Leopold, A. C., Crowe, L. M., and Crowe, L. H., Stability of dry liposomes in sugar glasses, Biophys. J., 70, 1769, 1996.
120. Ausborn, M., Schreier, H., Brezesinski, G., Fabian, H., Meyer, H. W., and Nuhn, P., The protective effect of free and membrane bound cryoprotectants during freezing and freeze-drying of liposomes, J. Controlled Rel., 30, 105, 1994.
121. Miyajima, K., Role of saccharides for the freeze-thawing and freeze drying of liposomes, Adv. Drug Del. Rev., 24, 151, 1997.
122. Crowe, L. M., Reid, D. S., and Crowe, L. H., Is trehalose special for preserving dry biomaterials?, Biophys. J., 71, 2087, 1996.
123. Rudolph, A. S., The freeze-dried preservation of liposome encapsulated hemoglobin: A potential blood substitute, Cryobiology, 25, 277, 1988.
124. Rudolph, A. S. and Cliff, R. O., Dry storage of liposome encapsulated hemoglobin: A blood substitute, Cryobiology, 27, 585, 1990.
125. Goodrich, R. P., Lyophilization of red blood cells, U.S. Patent 4,874,690, 1989.
126. Goodrich, R. P. and Williams, C. M., Lyophilization of cells, U.S. Patent 5,045,446, 1991.
127. Goodrich, R. P. and Williams, C. M., Lyophilized and reconstituted red blood cells and hemosome composition, U.S. Patent 5,043,261, 1991.
128. Goodrich, R. P., Sowemimo-Coker, S. O., Zerez, C. R., and Tanaka, K. R., Preservation of metabolic activity in lyophilized human erythrocytes, Proc. Nat. Acad. Sci. USA, 89, 967, 1992.
129. Grit, M. and Crommelin, D. J. A., Chemical stability of liposomes: Implications for their physical stability, Chem. Phys. Lipids, 64, 3, 1993.
130. Nelson, K. A. and Labuza, T. P., Relationship between water and lipid oxidation rates: Water activity and glass transition theory, in Lipid Oxidation in Food, St. Angelo, A. J., Ed., Washington DC: American Chemical Society, 1992.
131. Heckly, R. J. and Quay, J., Adventitious chemistry at reduced water activities: Free radicals and polyhydric agents, Cryobiology, 20, 613, 1983.
132. Ward, N. A., Milstein, J. B., Hull, H. F., Hull, B. P., and Kim-Farley, R. J., The WHO-EPI initiative for the global eradication of poliomyelitis, Biologicals, 21, 327, 1993.
133. World Health Organization, Global poliomyelitis eradication by the year 2000, WHO/EPI/ POLIO/92.2, 1992.
134. Sabin, A. B., Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world, J. Infect. Dis., 151, 420, 1985.
135. Melnick, J. L., Advantages and disadvantages of killed and live poliomyelitis vaccines, Bull. WHO, 56, 21, 1978.
136. Hogle, J. M., Chow, M., and Filman, D. J., Three-dimensional structure of poliovirus at 2.9 Å resolution, Science, 229, 1358, 1985.
137. Filman, D. J., Syed, R., Chow, M., Macadam, A. J., Minor, P., and Hogle, J. M., Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus, EMBO J., 8, 1567, 1989.
138. Putnak, J. R. and Phillips, B. A., Picornaviral structure and assembly, Microb. Rev., 45, 287, 1981.
139. Rossman, M. G., Arnold, E., Erickson, J. W., Frankenberger, E. A., Griffith, J. P., Hecht, H. J., Johnson, J. E., Kamer, G., Luo, M., Mosser, A. G., Rueckert, R. R., Sherry, B., and Vriend, G., Structure of a human common cold virus and functional relationship to other picornaviruses, Nature, 317, 145, 1985.
140. Acharya, R., Fry, E., Stuart, D., Fox, G., Rowlands, D., and Brown, F., The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution, Nature, 337, 709, 1989.
141. Rombaut, B., Verheyden, B., Andries, K., and Boeyé, A., Thermal inactivation of oral polio vaccine: Contribution of RNA and protein inactivation, J. Virol., 68, 6454, 1994.
142. Andries, K., Rombaut, B., Dewindt, B., and Boeyé, A., Discrepancy between infectivity and antigenicity stabilization of oral poliovaccine by a capsid-binding compound, J. Virol., 68, 3397, 1994.
143. McSharry, J. J., Caliguiri, L. A., and Eggers, H. J., Inhibition of uncoating of poliovirus by arildone, a new antiviral drug, Virology, 97, 307, 1979.
144. Grant, R. A., Hiremath, C. N., Filman, J. M., Syed, R., Andries, K., and Hogle, J. M., Structures of poliovirus complexes with anti-viral drugs: Implications for viral stability and drug design, Curr. Biol., 4, 784, 1994.
145. Mosser, A. G. and Rueckert, R., WIN 51711-dependent mutants of poliovirus type 3: Evidence that virions decay after release from cells unless drug is present, J. Virol., 67, 1246, 1993.
146. Dimmock, N., Differences between the thermal inactivation of picornaviruses at "high" and "low" temperatures, Virology, 31, 338, 1967.
147. Rombaut, B., Andries, K., and Boeyé, A., A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids, J. Gen. Virol., 72, 2153, 1991.
148. Grimmel, M., Zibirre, R., and Koch, G., Fluorescence spectrophotometric study of structural alterations in the capsid of poliovirus, Arch. Virol., 78, 191, 1983.
149. Volkin, D. B., Burke, C. J., Marfia, K. E., Oswald, C. B., Wolanski, B. and Middaugh, C. R., Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine, J. Pharm. Sci., 86, 666, 1997.
150. Newman, J. F. E., Tirrell, S., Ullman, C., Piatti, P. G., and Brown, F., Stabilizing oral poliovaccine at high temperatures, Vaccine, 13, 1431, 1995.
151. Magrath, D. I., Factors affecting the storage life of oral poliovaccine, in Proceedings of the Symposium on Stability and Effectiveness of Measles, Poliomyelitis, and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
152. Melnick, J. L. and Wallis, C., Effect of pH on thermal stabilization of oral poliovirus vaccine by magnesium chloride, Proc. Soc. Exp. Biol. Med., 112, 894, 1963.
153. Salo, R. J. and Cliver, D. O., Effect of acid pH, salts, and temperature on the infectivity and physical integrity of enteroviruses, Arch. Virol., 52, 269, 1976.
154. Lemon, S. L. and Milstien, J. B., The thermostability of vaccines, Int. J. Technol. Assess. Health Care, 10, 177, 1994.
155. Wallis, C. and Melnick, J. L., Cationic stabilization: A new property of enteroviruses, Virology, 16, 504, 1962.
156. 4 on the thermostability of viruses, Virology, 26, 694, 1965.
157. Fujioka, R., Kurtz, H., and Ackerman, W. W., Effects of cations and organic compounds on inactivation of poliovirus with urea, guanidine, and heat, Proc. Soc. Exp. Med., 132, 825, 1969.
158. Fujioka, R. and Ackerman, W. W., Evidence for conformational states of poliovirions: Effects of cations on reactivity of poliovirus to guanidine, Proc. Soc. Exp. Med., 148, 1070, 1975.
159. Peetermans, J., Colinet, G., and Stephenne, J., Activity of attenuated poliomyelitis and measles vaccines exposed at different temperatures, in Proceedings of the Symposium on Stability and Effectiveness of Measles, Poliomyelitis, and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
160. Sokhey, J., Gupta, C. K., Sharma, B., and Singh, H., Stability of oral polio vaccine at different temperatures, Vaccine, 6, 12, 1988.
161. Mirchamsy, H., Shafyi, A., Mahinpour, M., and Nazari, P., Stabilizing effect of magnesium chloride and sucrose on Sabin live polio vaccine, Dev. Biol. Stand., 41, 255, 1978.
162. Pohjanpelto, P., Stabilization of poliovirus by cystine, Virology, 6, 472, 1958.
163. Pohjanpelto, P., Thermal inactivation of poliovirus ribonucleic acid, Ann. Med. Exp. Biol. Fenn., 43, 65, 1965.
164. Halsted, C. C., Seto, D. S. Y., Simkins, J., and Carver, D. H., Protection of enteroviruses against heat inactivation by sulfhydryl-reducing substances, Virology, 40, 751, 1970.
165. Steele, F. M. and Black, F. L., Inactivation and heat stabilization of poliovirus by 2-thiouracil, J. Virol., 1, 653, 1967.
166. Carver, D. H. and Seto, D. S. Y., Viral inactivation by disulfide bond reducing agents, J. Virol., 2, 1482, 1968.
167. Pons, M., Stabilization of poliovirus by sodium tetrasulfide, Virology, 22, 253, 1964.
168. Salo, R. J. and Cliver, D. O., Inactivation of enteroviruses by ascorbic acid and sodium bisulfite, Appl. Environ. Microbiol., 36, 68, 1978.
169. Dorval, B. L., Chow, M., and Klibanov, A. M., Lysine and other diamines dramatically stabilize poliovirus against thermoinactivation, Biotechnol. Bioeng., 35, 1051, 1990.
170. Dorval, B. L., Chow, M., and Klibanov, A. M., Stabilization of poliovirus against heat inactivation, Biochem. Biophys. Res. Commun., 159, 1177, 1989.
171. Ofori-Anyinam, O., Vrijsen, R., Kronenberger, P., and Boeyé, A., Heat stabilized, infectious poliovirus, Vaccine, 13, 983, 1995.
172. Lemon, S. M. and Binn, L. N., Incomplete neutralization of hepatitis A virus in vitro due to lipid-associated virions, J. Gen. Virol., 66, 2501, 1985.
173. Melnick, J. L., Virus inactivation: Lessons from the past, Dev. Biol. Stand., 75, 29, 1991.
174. Roser, B. J., Preservation of viruses, U.S. Patent 5, 149, 653, 1992.
175. Berge, T. O., Jewett, R. L., and Blair, W. O., Preservation of enteroviruses by freeze-drying, Appl. Microbiol., 22, 850, 1971.
176. Milstien, J. B., Lemon, S. M., and Wright, P. F., Development of a more thermostable poliovirus vaccine, J. Infect. Dis., 175, Suppl. 1, S247, 1997.
177. Ferris, N. P., Philpot, R. M., Oxtoby, J. M., and Armstrong, R. M., Freeze-drying foot-and-mouth disease virus antigens, I. Infectivity studies, J. Virol. Methods, 29, 43, 1990.
178. Mandel, B., Uncoating-like modification of poliovirus capsid resulting from the cooperative effects of subfreezing temperature and submolar concentrations of urea, Arch. Virol., 71, 27, 1982.
179. World Health Organization, Expanded Programme on Immunization, Stability of oral polio vaccine after repeated freezing and thawing, Weekly Epidemiol. Rec., 65, 207, 1990.
180. 2O), Vaccine, 13, 1058, 1995.
181. 2O, WO Patent 9608273 A1, 1996.
182. Craniac, R., Wu, R., Otelea, D., Georgescu, M. M., Delpeyroux, F., Guillot, S., Balanant, J., and Tardy-Panit, M., The replacement of water with deuterium oxide significantly improves the thermal stability of the oral poliovirus vaccine, Dev. Biol. Stand., 87, 161, 1996.
183. Gould, E. A., Virus preservation and storage, in Cryopreservation and Freeze-Drying Protocols, Day, J. G. and McLellan, M. R., Eds., Totowa, NJ: Humana Press, 1995.
184. Rightsel, W. A. and Greiff, D., Freezing and freeze-drying of viruses, Cryobiology, 3, 106, 1967.
185. Clark, W. A. and Geary, D., Preservation of bacteriophages by freezing and freeze-drying, Cryobiology, 10, 351, 1973.
186. Wallis, C. and Melnick, J. L, Stabilization of enveloped viruses by dimethyl sulfoxide, J. Virol., 2, 953, 1968.
187. Grose, C., Friedrichs, W. E., and Smith, K. O., Cryopreservation of varicella-zoster virions without loss of structural integrity or infectivity, Intervirology, 15, 154, 1981.
188. Bellini, W. J., Rota, J. S., and Rota, P. A., Virology of measles virus, J. Infect. Dis., 170, S15, 1994.
189. Örvell, C., Measles virus, in Encyclopedia of Virology, vol. 2, Webster, R. G. and Granoff, A., Eds., New York: Academic Press, 1994.
190. Enders, J. F. and Peebles, T. C., Propagation in tissue cultures of cytopathic agents from patients with measles, Proc. Soc. Exp. Biol. Med., 86, 277, 1954.
191. Girardi, A. J., Warren, J., Goldman, C., and Jeffries, B., Growth and CF antigenicity of measles virus in cells deriving from human heart, Proc. Soc. Exp. Biol. Med., 98, 18, 1958.
192. Black, F. L., Growth and stability on measles virus, Virology, 7, 184, 1959.
193. Musser, S. J. and Underwood, G. E., Studies on measles virus, J. Immunol., 85, 292, 1960.
194. Arita, M. and Matumoto, M., Heat inactivation of measles virus, Jap. J. Microbiol., 12, 121, 1968.
195. Klamm, H., Pollex, G., and Henning, U., Thermal inactivation of different measles virus strains, Acta Virol., 35, 200, 1991.
196. Rapp, F., Butel, J., and Wallis, C., Protection of measles virus by sulfate ions against thermal inactivation, J. Bacteriol., 90, 132, 1965.
197. Sorodoc, Y., Cernescu, C., Aderca, I., Stability of antimeasles vaccine under the influence of some physical and chemical factors, Virologie, 30, 135, 1979.
198. Sorodoc, Y. and Cernescu, C., Patent application, OSIM File No. 95668, 1978.
199. Jarvis, D. L. and Garcia, A., Long-term stability of baculoviruses stored under various conditions, BioTechniques, 16, 508, 1994.
200. Gupta, C. K., Leszczynski, J., Gupta, R. K., and Siber, G. R., Stabilization of respiratory sysncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin, Vaccine, 14, 1417, 1996.
201. Mares, I., Kittnar, E., Srbova, H., and Casny, J., The lyophilization of measles virus, J. Hyg. Epidemiol. Microbiol. Immunol., 13, 279, 1969.
202. Goldner, H., Buynak, E. B., and Hilleman, M. R., Infectivity stability of live measles virus vaccine, Am. J. Dis. Child., 103, 440, 1962.
203. Enders, J. F., Katz, S. L., Milovanovic, M. V., and Holloway, A., Studies on an attenuated measles-virus vaccine, I. Development and preparation of the vaccine; technics for assay of effects of vaccination, N. Engl. J. Med., 263, 153, 1960.
204. McAleer, W. J., Markus, H. Z., McLean, A. A., Buynak, E. B., and Hilleman, M. R., Stability on storage at various temperatures of live measles, mumps, and rubella virus vaccines in new stabilizer, J. Biol. Stand., 8, 281, 1980.
205. Provost, P. J. and Nalin, D. R., Non-stinging measles-mumps-rubella vaccine composition, European Patent 0 514 208 A1, 1992.
206. de Rizzo, E., Tenorio, E. C., Mendes, I. F., Fang, F. L., Pral, M. M., Takata, C. S., Miyaki, C., Gallina, N. M., Tuchiya, H. N., and Akimura, O. K., Sorbitol-gelatin and glutamic acid-lactose solutions for stabilization of reference preparations of measles virus, Bull. Pan Am. Health Organ., 23, 299, 1989.
207. Makino, S., Sasaki, K., and Nakagawa, M., Stabilized live attenuated vaccine and its production, U.S. Patent, 4,985,244, 1991.
208. Damjanovic, V., Selective thermal effects on freeze-dried biological materials, Cryobiology, 12, 169, 1975.
209. Yoshioka, S., Aso, Y., Izutsu, K., and Terao, T., Application of accelerated testing to shelf-life prediction of commercial protein preparations, J. Pharm. Sci., 83, 454, 1994.
210. Franks, F., Accelerated stability testing of bioproducts: Attractions and pitfalls, Trends Biotech., 12, 114, 1994.
211. Greiff, D. and Rightsel, W. A., An accelerated storage test for predicting the stability of suspensions of measles virus dried by sublimation in vacuo, J. Immunol., 94, 395, 1965.
212. Cowdery, S., Frey, M., Orlowski, S., and Gray, A., Stability characteristics of freeze-dried human live virus vaccines, Dev. Biol. Stand., 36, 297, 1977.
213. Mann, G. F., Allison, L. M., Lloyd, J. S., Tam, P., Zuckerman, A. J., and Perkins, F. T., Stability of further-attenuated measles vaccines, Rev. Infect. Dis., 5, 482, 1983.
214. Greiff, D. and Damjanovic, V., Thermodynamic analysis of the degradation of suspensions of viruses dried by sublimation in vacuo, Suppl. Bull. Instit. Intern. Froid, 49, 1969.
215. Gelb, L. D., Varicella-zoster virus, in Virology, 2nd ed., Fields, B. N. and Knipe, D. M., Eds., New York: Raven Press, 1990.
216. Takahashi, M. and Gershon, A. A., Varicella vaccine, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
217. Weller, T. H., Serial propagation in vitro of agents producing inclusion bodies derived from varicella and herpes zoster, Proc. Soc. Exp. Biol. Med., 83, 340, 1953.
218. Caunt, A. E., The growth of varicella-zoster virus in human thyroid tissue cultures, Lancet, 2, 982, 1963.
219. Shiraki, K. and Takahashi, M., Virus particles and glycoproteins excreted from cultured cells infected with varicella-zoster virus (VZV), J. Gen. Virol., 61, 271, 1982.
220. Gèder, L., Jeney, E., and Gönczö, L, E., Growth of varicella virus in continuous monkey kidney and human thyroid cell cultures, Acta Microbiol. Acad. Sci. Hung., 11, 361, 1964.
221. Provost, P. J. and Wadsworth, C., Thermostable varicella zoster virus, PCT Patent WO 95/17503, 1995.
222. Hondo, R., Shebuta, H., and Matumoto, M., Lyophilization of varicella virus, Arch. Gesamte Virusforsch., 40, 397, 1973.
223. McAleer, W. J., Maigetter, R. Z., and Markus, H. Z., Stable lyophilized live herpes virus vaccine, U.S. Patent, 5,024,836, 1991.
224. Bennett, P. S., Maigetter, R. Z., Olson, M. G., Provost, P. J., Scattergood, E. M., and Schofield, T. L., The effects of freeze-drying on the potency and stability of live varicella virus vaccine, Dev. Biol. Stand., 74, 215, 1991.
225. Greiff, D. and Rightsel, W. A., Stability of suspensions of influenza virus dried to different contents of residual moisture by sublimation in vacuo, Appl. Microbiol., 16, 835, 1968.
226. Sparkes, J. D. and Fenje, P., The effect of residual moisture in lyophilized smallpox vaccine on its stability at different temperatures, Bull. WHO, 46, 729, 1972.
227. Asano, Y. and Takahashi, M., Studies on neutralization of varicella-zoster virus and serological follow-up of cases of varicella and zoster, Biken J., 21, 15, 1978.
228. Howell, C. L. and Miller, M. J., Effect of sucrose phosphate and sorbitol on infectivity of enveloped viruses during storage, J. Clin. Microbiol., 18, 658, 1983.
229. D'Hondt, L., Berge, E., Colinet, G., Duchene, M., and Peetermans, J., Production and quality control of the Oka-strain live varicella vaccine, Postgrad. Med. J., 61 Suppl 4, 53, 1985.
230. Meurice, F., De Bouver, J. L., Vandevoorde, D., Woods, S., and Bogaerts, H., Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children, J. Infect. Dis., 174, Suppl 3, S324, 1996.
231. Tan, A. Y. S., Connett, C. J., Connett, G. J., Quek, S. C., Yap, H. K., Meurice, F., and Lee, B. W., Use of reformulated Oka strain varicella vaccine (SmithKline Beecham biologicals/Oka) in healthy children, Eur. J. Pediatr., 155, 706, 1996.
232. Fanget, B. and Françon, A., A varicella vaccine stable at 5°C, in New Approaches to Stabilization of Vaccine Potency, Brown, F., Ed., Basel: S. Karger, 1996.
233. Fanget, B. and Françon, A., Stabilizers for live vaccines, PCT Application WO97/23238, 1997.
234. Koyama, K. and Osame, J., Stabilized live vaccine, European Patent Application 0,568,726 A2, 1992.
235. Ward, R. L. and Ashley, C. S., Comparative study on the mechanisms of rotavirus inactivation by sodium dodecyl sulfate and ethylenediaminetetraacetate, Appl. Environ. Microbiol., 39, 1148, 1980.
236. Starke, J. R. and Connelly, K. K., Bacille Calmette-Guérin vaccine, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
237. Calmette, A., Boquet, A., and Negre, L., Contribution á l'étude du bacille tuberculeux bilie, Ann. Inst. Pasteur, 9, 561, 1921
238. Rosenthal, S. R., Vaccines other than BCG used against tuberculosis, in BCG Vaccine: Tuberculosis - Cancer, Littleton, MA: PSG Publishing, 1980.
239. Crispen, R. G., BCG and cancer, Dev. Biol. Stand., 58, 371, 1986.
240. O'Donnell, M. A. and DeWolf, W. C., Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer, Surg. Oncol. Clin. N. Am., 4, 189, 1995.
241. Ambrosch, F., Wiedermann, G., and Krepler, P., Studies on the influence of BCG vaccination on infantile leukemia, Dev. Biol. Stand., 58, 419, 1986.
242. Lenner, R., BCG against tuberculosis, Conn. Med., 60, 329, 1996.
243. Torisu, M., Iwasaki, K., and Sakata, M., Immunotherapy of cancer patients with BCG: Summary of ten years' experience in Japan, Dev. Biol. Stand., 58, 451, 1986.
244. Stover, C. F., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., Snapper, S. B., Barletta, R. G., Jacobs, W. R., Jr., and Bloom, B. R., New use of BCG for recombinant vaccines, Nature, 351, 456, 1991.
245. Stover, C. F., de la Cruz, V. F., Bansal, G. P., Hanson, M. S., Fuerst, T. R., Jacobs, W. R., Jr., and Bloom, B. R., Use of recombinant BCG as a vaccine delivery vehicle, in Genetically Engineered Vaccines, Ciardi, J. E., McGhee, J. R., and Keith, J. M., Eds., New York: Plenum Press, 1992.
246. Hanson, M. S., Bansal, G. P., Langermann, S., Stover, C. K., and Orme, I., Efficacy and safety of live recombinant BCG vaccines, Dev. Biol. Stand., 84, 229, 1995.
247. Gheorghiu, M. and Lagrange, P. H., Viability, heat stability, and immunogenicity of four BCG vaccines prepared from four different BCG strains, Ann. Immunol., 134C, 125, 1983.
248. Stainer, D. W. and Landi, S., Stability of BCG vaccines, Dev. Biol. Stand., 58, 119, 1986.
249. Devadoss, P. O., Klegerman, M. E., and Groves, M. J., A scanning electron microscope study of mycobacterial developmental stages in commercial BCG vaccines, Curr. Microbiol., 22, 247, 1991.
250. WHO Expert Committee on Biological Standardization, Revised requirements for freeze-dried BCG vaccine. (Requirements for Biological Substances N°11) (Revised 1978), WHO Techn. Rep. Ser., 638, 116, 1979.
251. Gheorghiu, M., Lagranderie, M., and Balazuc, A. M., Stabilization of BCG vaccines, Dev. Biol. Stand., 87, 251, 1996.
252. Milstien, J. B. and Gibson, J. J., Quality control of BCG vaccine by WHO: A review of factors that may influence vaccine effectiveness and safety, Bull. WHO, 68, 93, 1990.
253. Miller, R., Jr. and Goodner, K., Studies on the stability of lyophilized BCG vaccine, Yale J. Biol. Med., 25, 262, 1953.
254. Sparkes, J., Guest, N., Csizer, Z. and Barreto, L., Stability of BCG vaccine (intravesical) TERACYS™/BCG therapeutic IMMUCYST™ and its importance in clinical efficacy, Dev. Biol. Stand., 77, 217, 1992.
255. Suire, A. and Gheorghiu, M., An interlaboratory comparative assay of viability and heat stability control of different BCG vaccines on two solid culture media, Dev. Biol. Stand., 58, 155, 1986.
256. Rodopska, S., Les souches BCG: Lyophilisation et activite biologique, Symp. Ser. Immunobiol. Standard., 17, 169, 1971.
257. Kim, T. H., High-viability lyophilized Bacille Calmette-Guérin vaccine produced by deep-culture technique, Appl. Envir. Microbiol., 34, 495, 1977.
258. Gheorghiu, M., Lagrange, P. H., and Fillastre, C., The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine, J. Biol. Stand., 16, 15, 1988.
259. Osborn, T. W., Changes in BCG strains, Tubercle, 64, 1, 1983.
260. Pruchova, J., Mara, M., Mohelska, H., Sir, Z., and Galliova, J., Some biological, biochemical and morphological changes and their correlations in selected BCG vaccine strains, J. Biol. Stand., 4, 319, 1976.
261. Chouchkova, M. and Engibarov, A., Studies on the biological activity of two strains of BCG: Influence of production conditions, Dev. Biol. Stand., 58, 105, 1986.
262. Stavri, D., Stavri, H., and Draghici, D., Selection of a BCG population with increased freeze-drying resistance, Dev. Biol. Stand., 58, 139, 1986.
263. Freudenstein, H., Long-term stability of BCG vaccine sealed in ampoules under nitrogen with reference to its short-term heat resistance, Dev. Biol. Stand., 58, 133, 1986.
264. Corbel, M. J., Reasons for instability of bacterial vaccines, Dev. Biol. Stand., 87, 113, 1996.
265. Adams, G. D. J., The preservation of inocula, in Microbiological Quality Assurance, Brown, M. R. W. and Gilbert, P., Eds., Boca Raton, FL: CRC Press, 1995.
266. Rudge, R. H., Maintenance of bacteria by freeze-drying, in Maintenance of Microorganisms: A Manual of Laboratory Methods, Kirsop, B. E. and Snell, J. J. S., Eds, London: Academic Press, 1994.
267. Ashwood-Smith, M. J., Preservation of microorganisms by freezing, freeze-drying, and desiccation, in Low Temperature Preservation in Medicine and Biology, Ashwood-Smith, M. J., Ed., Tunbridge Wells, UK: Pitman Medical, 1980.
268. Heckly, R. J., Preservation of microorganisms, Adv. Appl. Microbiol., 24, 1, 1978.
269. Simione, F. P., Key issues relating to the genetic stability and preservation of cells and cell banks J. Par. Sci. Tech., 46, 226, 1992.
270. Heckly, R. J. and Quay, J., A brief review of lyophilization damage and repair in bacterial preparations, Cryobiology, 18, 592, 1981.
271. Orndorff, G. R. and MacKenzie, A. P., The function of the suspending medium during freeze-drying preservation of Escherichia coli, Cryobiology, 10, 475, 1973.
272. MacKenzie, A. P., Comparative studies on the freeze-drying survival of various bacteria: Gram type, suspending medium, and freezing rate, Dev. Biol. Stand., 36, 263, 1976.
273. Leslie, S. M., Israeli, E., Lighthart, B., Crowe, J. H., and Crowe, L. M., Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying, Appl. Environ. Microbiol., 61, 3592, 1995.
274. Souzu, T. N. H. and Araki, T., Effect of residual moisture content on the survival of freeze-dried bacteria during storage under various conditions, Cryobiology, 2, 276, 1966.
275. Wilding, I. R., Davis, S. S., and O'Hagen, D. T., Targeting of drugs and vaccines to the gut, Pharmacol. Ther., 62, 97, 1994.
276. O'Hagan, D. T., The intestinal uptake of particles and the implications for drug and antigen delivery, J. Anat., 189, 477, 1996.
277. Po, A. L. W., Rogers, E., Shepphard, M., and Scott, E. M., Delivery systems for non-parenteral vaccines, Adv. Drug Deliv. Rev., 18, 101, 1995.
278. Powell, M. F. and Newman, M. J., Eds., Vaccine Design: The Subunit and Adjuvant Approach, New York: Plenum Press, 1995.
279. Walker, R. I., New strategies for using mucosal vaccination to achieve more effective immunization, Vaccine, 12, 387, 1994.
280. Kiyono, H., Ogra, P. L., and McGhee, J. R., Eds., Mucosal Vaccines, San Diego, CA: Academic Press, 1996.
281. Clements, J. D., Bao, J. X., and Cárdenas, L., Use of attenuated bacteria as live oral vaccine vectors, in Novel Delivery Systems for Oral Vaccination, O'Hagan, D. T., Ed., Boca Raton: CRC Press, 1994.
282. Darji, A., Guzman, C. A., Gerstel, B., Wachholz, P., Timmis, K. N., Wehland, J., Chakraborty, T., and Weiss, S., Oral somatic transgene vaccination using attenuated S. typhimurium, Cell, 91, 765, 1997.
283. Rubin, B. A. and Rorke, L. B., Adenovirus vaccines, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
284. Tint, H., Tablet dosage-form for the immunization of the intestinal tract with live virus preparations, U.S. Patent 3,458,621, 1969.
285. Lubeck, M. D., David, A. R., Chengalvala, M., Natuk, R. J., Morin, J. E., Molnar-Kimber, K., Mason, B. B., Bhat, B. M., Mizutani, S., Hung, P. P, and Purcell, R. H., Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus, Proc. Nat. Acad. Sci. USA, 86, 6763, 1989.
286. Tacket, C. O., Losonsky, G., Lubeck, M. D., Davis, A. R., Mizutani, S., Horwith, G., Hung, P., Edelman, R., and Levine, M. M., Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine, Vaccine, 10, 673, 1992.
287. Kalicharran, K. K., Springthorpe, V. S., and Sattar, S. A., Studies on the stability of a human adenovirus-rabies recombinant vaccine, Cancer J. Vet. Res., 56, 28, 1992.
288. Tang, D. C., Shi, Z., and Curiel, D. T., Vaccination onto bare skin, Nature, 388, 729, 1997.
289. Rosenthal, K. L., Copeland, K. F. T., and Gallichan, W. S., Recombinant adenoviruses as vectors for mucosal immunity, in Mucosal Vaccines, Kiyono, H., Ogra, P. L., and McGhee, J. R., Eds., San Diego, CA: Academic Press, 1996.
290. Hoft, D. F. and Gheorghiu, M., Mucosal immunity induced by oral administration of Bacille Calmette-Guérin, in Mucosal Vaccines, Kiyono, H., Ogra, P. L., and McGhee, J. R., Eds., San Diego, CA: Academic Press, 1996.
291. Hochstein-Mintzel, V., Stickl, H., and Huber, H. C., Oral immuniziation against smallpox, Dev. Biol. Stand., 33, 260, 1976.
292. Couch, R. B., Cate, T. R., and Keitel, W. A., Oral immunization with influenza virus vaccines, in Mucosal Vaccines, Kiyono, H., Ogra, P. L., and McGhee, J. R., Eds., San Diego, CA: Academic Press, 1996.
293. Evans, D. J., McKeating, J., Meredith, J. M., Burke, K. L., Katrak, K., John, A., Ferguson, M., Minor, P. D., Weiss, R. A., and Almond, J. W., An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies, Nature, 339, 385, 1989.
294. Ishihara, K., Ikeda, S., Arai, E., and Sawada, T., Treatment of malignant skin tumours with oral administration of BCG in enteric-coated capsules, Dev. Biol. Stand., 58, 465, 1986.
295. Forrest, B. D., Clinical evaluation of attenuated Salmonella typhi vaccines in human subjects, in Novel Delivery Systems for Oral Vaccines, O'Hagan, D. T., Ed., Boca Raton, FL: CRC Press, 1994.
296. Cryz, S. J., Pasteris, O., Varallyay, S. J., and Furer, E., Factors influencing the stability of live oral attenuated bacterial vaccines, Dev. Biol. Stand., 87, 277, 1996.
297. Levine, M. M., Ferreccio, C., Cryz, S., and Ortiz, E., Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomized controlled field trial, Lancet, 336, 891, 1990.
298. Cryz, S. J., Levine, M. M., Kaper, J. B., Furer, E., and Althaus, B., Randomized double blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults, Vaccine, 8, 577, 1990.
299. Sack, D. A., Shimko, J., Sack, R. B., Gomes, J. G., MacLeod, K., O'Sullivan, D., and Spriggs, D., Comparison of alternate buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers, Infect. Immun., 65, 2107, 1997.
300. Kapikian, A. Z., Hoshino, Y., Chanock, R. M., and Perez-Schael, I., Efficacy of quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children, J. Infect. Dis., 174, Suppl. 1, S65, 1996.
301. Clark, H. F., Offit, P. A., Ellis, R. W., Eiden, J. J., Krah, D., Shaw, A. R., Pichichero, M., Treanor, J. J., Borian, F. E., Bell, L. M., and Plotkin, S. A., The development of multivalent bovine rotavirus (strainWC3)reassortant vaccine for infants, J. Infect. Dis., 174 (Suppl 1), 873, 1996.
302. Vesikari, T., Isolauri, E., D'Hondt, E., Delem, A., and André, F. E., Increased "take" rate of oral rotavirus vaccines in infants after milk feeding, Lancet, 2, 700, 1984.
303. Weiss, C. and Clark, H. F., Acid inactivation of rotavirus by exposure to acid buffer or acidic gastric juice, J. Gen. Virol., 66, 2725, 1985.
304. Pichichero, M. E., Marsocci, S. M., Francis, A. B., Green, J. L., Disney, F. A., Rennels, M. B., Lewis, E. D., Sugarman, L., Losonsky, G. A., Zito, E., and Davidson, B. L., A comparitive evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2, and 4 and combined (tetravalent) vaccines in healthy infants, Vaccine, 11, 747, 1993.
305. Ing, D. J., Glass, R. I, Woods, P. A., Simonetti, M., Pallansch, M. A., Wilcox, W. D., Davidson, B. L., and Sievert, A. J., Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine, Am. J. Dis. Child., 145, 892, 1991.
306. Rennels, M. B., Glass, R. I., Dennehy, P. H., Berstein, D. I., Pichichero, M. E., Zito, E. T., Mack, M. E., Davidson, B. L., and Kapikian, A. Z., Safety and efficacy of high-dose rhesus reassortant rotavirus vaccines: Report of the national multicenter trial, Pediatrics, 97, 7, 1996.
307. Joensuu, J., Koskenniemi, E., Pang, X.-L., and Vesikari, T., Randomized placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis, Lancet, 350, 1205, 1997.
308. Pérez-Schael, I., Guintiñas, M. J., Pérez, M., Pagone, V., Rojas, A. M., González, R., Cunto, W., Hoshino, Y., and Kapikian, A. Z., Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela., N. Engl. J. Med., 337, 1181, 1997.
309. Offit, P. A., Khoury, C. A., Moser, C. A., Clark, H. F., Kim, J. E., and Speaker, T. J., Enhancement of rotavirus immunogenicity by microencapsulation, Virology, 203, 134, 1994.
310. Brown, K. A., Moser, C. A., Speaker, T. J., Khoury, C. A., Kim, J. E., and Offit, P. A., Enhancement by microencapsulation of rotavirus specific intestinal immune responses in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture, J. Infect. Dis., 171, 1334, 1995.
311. Moser, C. A., Speaker, T. J., and Offit, P. A., Effect of water-based microencapsulation on protection against EDIM rotavirus challenge in mice, J. Virol., 72, 3859, 1998.
312. Moser, C. A., Speaker, T. J., Berlin, J. A., and Offit, P. A., Aqueous-based microencapsulation enhances virus-specific humoral immune responses in mice after parenteral inoculation, Vaccine, 14, 1235, 1996.
313. Periwal, S. B., Speaker, T. J., and Cebra, J. J., Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates, J. Virol., 71, 2844, 1997.
314. Duncan, J. D., Wang, P. X., Harrington, C. M., Schafer, D. P., Matsuoka, Y., Mestecky, J. F., Compans, R. W., and Novak, M. J., Comparative analysis of oral delivery systems for live rotavirus vaccines, J. Controlled Rel., 41, 237, 1996.
315. Nir, S., Duzgunes, N., Pedroso de Lima, M. C., and Hoekstra, D., Fusion of enveloped viruses with cells and liposomes: Activity and inactivation, Cell Biophys., 17, 181, 1990.
316. Gregoriadis, G., Liposomes as immunoadjuvants and vaccine carriers: Antigen entrapment, Immunomethods, 4, 210, 1994.
317. Antimisiaris, S. G., Jayasekera, P., and Gregoriadis, G., Liposomes as vaccine carriers: Incorporation of soluble and particulate antigens in giant vesicles, J. Immunol. Methods, 166, 271, 1993.
318. Bhagat, H. R., Dalal, P. S., and Nellore, R., Oral vaccination by microspheres, in Microparticulate Systems for the Delivery of Proteins and Vaccines, Cohen, S. and Berstein, H., Eds., New York: Marcel Dekker, 1996.
319. Kissel, T. and Koneberg, R., Injectable biodegradable microspheres for vaccine delivery, in Microparticulate Systems for the Delivery of Proteins and Vaccines, Cohen, S. and Berstein, H., Eds., New York: Marcel Dekker, 1996.
320. Sanchez, A., Gupta, R., Alonso, M. J., Siber, G. R., and Langer, R., Pulsed controlled-release system for potential use in vaccine delivery, J. Pharm. Sci., 85, 547, 1996.
321. Moldoveanu, Z., Novak, M., Huang, W. Q., Gilley, R., Staas, J. K., Schafer, D., Compans, R. W., and Mestecky, J., Oral immunization with influenza virus in biodegradable microspheres, J. Infect. Dis., 167, 84, 1993.
322. Greenway, T. E., Eldridge, J. H., Ludwig, G., Staas, J. K., Smith, J. F., Gilley, R. M., and Michalek, S. M., Enhancement of protective responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine, Vaccine, 13, 1411, 1995.
323. Marx, P. A., Compans, R. W., Gettie, A., Staas, J. K., Gilley, R. M., Muligan, M. J., Yamshchikov, G. V., Chen, D., and Eldridge, J. H., Protection against vaginal SIV transmission with microencapsulated vaccine, Science, 260, 1323, 1993.
324. Ray, R., Novak, M., Duncan, J. D., Matsuoka, Y., and Compans, R. W., Microencapsulated human parainfluenza virus induces a protective immune response, J. Infect. Dis., 167, 752, 1993.
325. Hilfinger, J. M., Tsume, Y., Beer, S., Davidson, B., Crison, J. R., and Amidon, G. L., Extended release of recombinant adenovirus from PLGA microspheres, Proc. Int. Symp. Controlled Release Bioact. Mater., 23, 915, 1996.
326. Beer, S. J., Hilfinger, J. M., and Davidson, B. L., Extended release of adenovirus from polymer microspheres: Potential use in gene therapy for brain tumors, Adv. Drug. Del. Rev., 27, 59, 1997.
327. Trouwborst, T., Kuyper, S., de Jong, J. C., and Plantinga, A. D., Inactivation of some bacterial and animal viruses by exposure to liquid-air interfaces, J. Gen. Virol., 24, 155, 1974.
328. Harper, G. J., Airborne micro-organisms: Survival tests with four viruses, J. Hyg. (Camb.), 59, 479, 1961.
329. Barlow, D. F., The effects of various protecting agents on the inactivation of foot-and-mouth disease virus in aerosols and during freeze drying, J. Gen. Virol., 17, 281, 1972.
330. Cox, C. S., Harris, W. J., and Lee, J., Viability and electron microscope studies of phages T3 and T7 subjected to freeze-drying, freeze-thawing and aerosolization, J. Gen. Microbiol., 81, 207, 1974.
331. Lanza, R. P., Hayes, J. L., and Chick, W. L., Encapsulated cell technology, Nature Biotech., 14, 1107, 1996.
332. Tamura, S. I. and Kurata, T., Intranasal immunization with influenza vaccine, in Mucosal Vaccines, Kiyono, H., Ogra, P. L., and McGhee, J. R., Eds., San Diego, CA: Academic Press, 1996.
333. Maassab, H. F., Shaw, M. W., and Heilman, C. A., Live influenza virus vaccines, in Vaccines, 2nd ed., Plotkin, S. A. and Mortimer, E. A., Eds., Philadelphia, PA: W. B. Saunders, 1994.
334. Belshe, R. B., Mendelman, P. M., Treanor, J., King, J., Gruber, W. C., Piedra, P., Bernstein, D. I., Hayden, F. G., Kotloff, K., Zangwill, K., Iacuzio, D., and Wolff, M., The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children, N. Engl. J. Med., 338, 1405, 1998.
335. Kendal, A. P., Maassab, H. F., Alexandrova, G. I., and Ghendon, Y. Z., Development of cold-adapted recombinant live, attenuated influenza A vaccines in the U.S.A. and U.S.S.R., Antiviral Res., 1, 339, 1981.
336. Renauld-Mongenie, G., Mielcarek, N., Cornette, J., Schacht, A. M., Capron, A., Riveau, G., and Locht, C., Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis, Proc. Nat. Acad. Sci. USA, 93, 7944, 1996.
337. Brown, A. R., George, D. W., and Matteson, D. K., Vaccinator device for delivering propellant-driven aerosols of Streptococcus suis bacteria into the respiratory tracts of swine, Vaccine, 15, 1165, 1997.
338. Hickey, A. J. and Dunbar, C. A., A new millennium for inhalation technology, Pharm. Technol., June, 116, 1997.
339. Aylward, B., Lloyd, J., Zaffran, M., McNair-Scott, R., and Evans, P., Reducing the risk of unsafe injections in immunization programmes: Financial and operational implications of various injection technologies, Bull. WHO, 73, 531, 1995.
340. Zachoval, R., Deinhardt, F., Gürtler, L., Eisenburg, J., and Korger, G., Risk of virus transmission by jet injection, Lancet, 1, 189, 1988.
341. Matheï, C., Van Damme, P., and Meheus, A., Hepatitis B vaccine administration: Comparison between jet-gun and syringe and needle, Vaccine, 15, 402, 1997.
342. Parent du Châtelet, I., Lang, J., Schlumberger, M., Vidor, E., Soula, G., Genet, A., Standaert, S. M., Saliou, P., and Imule® Investigators Group, Clinical immunogenicity and toleracne studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule®): Comparison with standard syringe injection, Vaccine, 15, 449, 1997.
343. Maas, A. J. J. and Brink, P. R. G., Some physical aspects of the medical jet injector, Med. Biol. Eng. Comput., 25, 81, 1983.
344. Neufeld, P. D. and Katz, L., Comparative evaluation of three jet injectors for mass immunization, Cancer J. Public Health, 68, 513, 1977.
345. Kok, P. W., Kenya, P. R., and Ensering, H., Measles immunization with further attenuated heat-stable measles vaccine using five different methods of administration, Trans. R. Soc. Trop. Med. Hyg., 77, 171, 1983.
346. Volkin, D. B., Burke, C. J., Sanyal, G., and Middaugh, C. R., Analysis of vaccine stability, Dev. Biol. Stand., 87, 135, 1996.
347. Facts and Comparisons, ImmunoFacts: Vaccines and immunologic drugs, Facts and Comparisons, St. Louis, 1993.
348. Wigand, R., Bachmann, P., and Brandner, G., Stabilization of isometric DNA viruses against thermoinactivation by lowered ionic strength, Arch. Virol., 69, 61, 1981.
349. Casto, B. C. and Hammon, W. M., Conditions affecting the stability of a simian adenovirus in the presence of magnesium chloride, Proc. Soc. Exp. Biol. Med., 122, 1216, 1966.
350. Yamamoto, T., The effect of ion concentration and pH on the thermal stability of a canine adenovirus, Cancer J. Microbiol., 13, 1139, 1967.
351. Wallis, C., Yang, C. S., and Melnick, J. L., Effect of cations on thermal inactivation of vaccinia, herpes simplex, and adenoviruses, J. Immunol., 89, 41, 1962.
352. Estes, M. K. and Butel, J. S., Characterization of a temperature-sensitive mutant of human adenovirus type 7, J. Virol., 21, 1159, 1977.
353. Akel, H. M. O., Furarah, A. M., and Sweet, C., Further studies of 31 temperature-sensitive mutants of mouse cytomegalovirus: Thermal stability, replication and analysis of temperature-sensitive funtions by temperature shift, FEMS Microbiol. Lett., 114, 311, 1993.
354. Doel, T. R. and Baccarini, P. J., Thermal stability of foot-and-mouth disease virus, Arch. Virol., 70, 21, 1981.
355. Razdan, R., Sen, A. K., Rao, B. V., and Suryanarayana, V. V. S., Stability of foot-and-mouth disease virus, its genome and proteins at 37°C, Acta Virol., 40, 9, 1996.
356. Vande Woude, G. F., The inactivation of foot-and-mouth disease virus at ionic-strength dependent isoelectric points, Virology, 31, 436, 1967.
357. MacKenzie, J. S., Slade, W. R., Lake, J., Priston, R. A. J., Bisby, J., Laing, S., and Newman, J., Temperature-sensitive mutants of foot-and-mouth disease virus: The isolation of mutants and observations on their properties and genetic recombination, J. Gen. Virol., 27, 61, 1975.
358. Siegl, G., Weitz, M., and Kronauer, G., Stability of hepatitis A virus, Intervirology, 22, 218, 1984.
359. Scholz, E., Heinricy, U., and Flehmig, B., Acid stability of hepatitis A virus, J. Gen. Virol., 70, 2481, 1989.
360. Parry, J. V. and Mortimer, P. P., The heat sensitivity of hepatitis A virus determined by a simple tissue culture method, J. Med. Virol., 14, 277, 1984.
361. Anderson, D. A., Cytopathology, plaque assay, and heat inactivation of hepatitis A virus strain HM175, J. Med. Virol., 22, 35, 1987.
362. Lancz, G. and Sample, J., Thermal-pH inactivation of herpes simplex virus: Interdepedence of the medium composition and the pH on the rate of virus inactivation, Arch. Virol., 84, 141, 1985.
363. Lancz, G., Effect of pH on the kinetics of herpes simplex virus inactivation at 36°, Virology, 75, 488, 1976.
364. Lancz, G., Influence of environmental pH on the preservation and inactivation of herpes simplex virus, Proc. Soc. Exp. Biol. Med., 162, 238, 1979.
365. Wallis, C. and Melnick, J. L., Thermostabilization and thermosensitization of herpesvirus, J. Bacteriol., 90, 1632, 1965.
366. Haspel, M. V. and Sugiura, A., Heat stability of influenza viral infectivity as a host-controlled phenotype, Arch. Ge. Virusforsch., 35, 308, 1971.
367. Lauffer, M. A., Carnelly, H. L., and MacDonald, E., Thermal destruction of influenza A virus infectivity, Arch. Biochem., 16, 321, 1948.
368. Nakamura, M. and Eguchi, K., A comparison of the inactivation of japanese enchepalitis virus by deoxycholate and ether, J. Gen. Virol., 2, 1, 1968.
369. Darwish, M. A. and Hammon, W. M., Studies on Japanese B enchepalitis virus vaccines from tissue culture, VI. Development of a hamster kidney tissue culture inactivated vaccine for man. J. Immumol, 96, 806, 1966.
370. Nishimura, C., Nomura, M., and Kitaoka, M., Study on urea inactivation of japanese encephalitis virus, Jpn. J. Med. Sci. Biol., 20, 377, 1967.
371. Ikic, D., Juzbasic, M., Cimbur-Screiber, T., and Rajninger-Miholoc, M., Stability of live freeze-dried measles vaccine at various temperatures, in Proc. Symp. Stability and Effectiveness of Measles, Poliomyelitis and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
372. Cohen, H. and Bos, J. M., The influence of storage at 37°C on the potency of freeze-dried and reconstituted live measles vaccine in Proc. Symp. Stability and Effectiveness of Measles, Poliomyelitis and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
373. Peetermens, J. H., Colinet, G., Stephenne, J., and Bouillet, A., Stability of freeze dried measles vaccines, Dev. Biol. Stand., 41, 259, 1978.
374. World Health Organization, Expanded programme on immunization, Heat stability of poliovirus and measles vaccines, Wkly. Epidemiol. Rec., 63, 349-352, 1988.
375. Ikic, D., Juzbasic, M., Cimbur-Screiber, T., Rajninger-Miholoc, M., and Delimar, N., Thermostability of live freeze-dried measles vaccine after reconstitution, in Proc. Symp. Stability and Effectiveness of Measles, Poliomyelitis and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
376. Yoshizawa, S., Hashizume, S., Miyamura, K., and Matumoto, M., Variation in thermostability of measles virus, Japan J. Microbiol., 20, 243, 1976.
377. McAleer, W. J. and Markus, H. Z., Vaccine stabilizer, U.S. Patent 4,147,772, 1979.
378. D'Hondt, E., Stabilisants améliorés pour vaccins atténués, procédé pour leur préparation et vaccins les contenant, European Patent 252059 A2, 1988.
379. Françon, A. J.-L. and Montagnon, B. J., Procédé de stabilisation des vaccins et associations de vaccins à virus atténués conservés sous forme lyophilisée, et compositions obtenues, European Patent 353108 A1, 1989.
380. Kehrer, S., Verfahren zur Stabilisierung eines Lebendvirusimpfstoffes gegenüber Temperatureinwirkung, German Patent DD 299213 A7, 1992.
381. Greiff, D., Rightsel, W. A., and Schuler, E. E., Effect of freezing, storage at low temperatures, and drying by sublimation in vacuo on the activities of measles virus, Nature, 202, 624, 1964.
382. Françon, A. J., Bernard, B., and Montagnon, J., Stabilizing vaccines, U.S. Patent 5,075,110, 1991.
383. Arimura, H., Uemura, Y., and Okuno, Y., Live mumps vaccine and method of stabilizing the same, U.S. Patent 4,555,401, 1985.
384. Newman, J. F. E., Tirrell, S., Ullman, C., Piatti, P. G., and Brown, F., Stabilizing oral poliovaccine at high temperatures, Dev. Biol. Stand., 87, 103, 1996.
385. Rombaut, B., Andries, K., and Boeyé, A., Stabilisation of poliovirus with pirodavir, Dev. Biol. Stand., 87, 173, 1996.
386. Dorval, B. L., Chow, M., and Klibanov, A. M., Stabilized vaccine compositions, WO Patent 91/02543, 1991.
387. Fox, P. A., Otto, M. J., and McKinlay, M. A., Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug, Antimicrob. Agents Chemother., 110, 1986.
388. Couderc, T., Hogle, J., Le Blay, H., Horaud, F., and Blondel, B., Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: Involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell, J. Virol., 67, 3808, 1993.
389. Kong, J., Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries, Chung Hua Liu Hsing Ping Hsueh Tsa Chih, 14, 151, 1993.
390. Murdin, A. D., Kameda, A., Murray, M. G., and Wimmer, E., Phenotypic characterization of antigenic hybrids of poliovirus, Microb. Pathog., 10, 39, 1991.
391. Younger, J. S., Thermal inactivation studies with different strains of poliovirus, J. Immunol., 78, 282, 1957.
392. McCahon, D. and Cooper, P. D., Infection of poliovirus temperature-sensitive mutants having defects in virus structural protein, J. Gen. Virol., 6, 51, 1970.
393. Mauler, R. and Gruschkau, H., On stability of oral poliovirus vaccines, Dev. Biol. Stand., 41, 267, 1978.
394. Michalski, F., Parks, N. F., Sokol, F., and Clark, H. F., Thermal inactivation of rabies and other rhabdoviruses: Stabilization by the chelating agent ethylenediamintetraacetic acid at physiological temperatures, Infect. Immun., 14, 135, 1976.
395. Gupta, C. K., Leszczynski, J., Gupta, R. K., and Siber, G. R., Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin, Vaccine, 14, 1417, 1996.
396. Weiss, C. and Clark, H. F., Acid inactivation of rotaviruses by exposure to acid buffer or acidic gastric acid, J. Gen. Virol., 66, 2725, 1985.
397. Vesikari, T., Isolauri, E., D'Hondt, E., Delem, A., and André, F. E., Increased "take" rate of oral rotavirus vaccine in infants after milk feeding, Lancet, 2, 700, 1984.
398. Meng, Z. D., Birch, C., Heath, R., and Gust, I., Physicochemical stability and inactivation of human and simian rotaviruses, Appl. Env. Microbiol., 53, 727, 1987.
399. Estes, M. K., Graham, D. Y., Smith, E. M., and Gerba, C. P., Rotavirus stability and inactivation, J. Gen. Virol., 43, 403, 1979.
400. Shirley, J. A., Beards, G. M., Thouless, M. E., and Flewett, T. H., The influence of divalent cations on the stability of human rotavirus, Arch. Virol., 67, 1, 1981.
401. Hekker, A. C, Smith, L., and Huisman, P., Stabilizer for lyophilization of rubella virus, Arch. Ge. Virusforsch., 29, 257, 1970.
402. Peetermans, J., Colinet, G., and Huygelen, C., Stability of freeze-dried rubella virus vaccine (Cendehill® strain) at various temperatures, J. Biol. Stand., 1, 179, 1973.
403. Zygraich, N. and Peetermens, J., Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them, U.S. Patent 3,915,794, 1973
404. Hekker, A. C., Bos, J. M., and Smith, L., A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells, J. Biol. Stand., 1, 21, 1973.
405. Suzuki, M., Effect of suspending media on freeze-drying and preservation of vaccinia virus, J. Hyg. (Camb.), 68, 29, 1970.
406. Suzuki, M., Protectants in the freeze-drying and the preservation of vaccinia virus, Cryobiology, 10, 435, 1973.
407. Suzuki, M., Stability and residual moisture content of dried vaccinia virus, Cryobiology, 10, 432, 1973.
408. Yamanouchi, K. and Barrett, T., Progress in the development of a heat-stable recombinant rinderpest vaccine using an attenuated vaccinia virus vector, Rev. Sci. Tech. Off. Int. Epizoot., 13, 721, 1994.
409. Osaka Univ. Res., Stable, dry smalpox vaccine preparation using arginine (salts) as stabilizer, JP J72037526-B, 1972.
410. Hondo, R., Shibuta, H., and Matumoto, M., An improved plaque assay for varicella virus, Arch. Virol., 51, 355, 1976.
411. Levin, M. J., Leventhal, S., and Masters, H. A., Factors influencing quantitative isolation of varicella-zoster virus, J. Clin. Microbiol., 19, 880, 1984.
412. Barme, M. and Bronner, C., Thermostabilisation du vaccin antiamaril 17D lyophilisé, I. Essai de substances protectrices, J. Biol. Stand., 12, 435, 1984.
413. Sood, D. K., Aggarwal, S. B., Sharma, S. B., Sokhey, J., and Singh, H., Study on the stability of 17D-204 yellow fever vaccine before and after stabilization, Vaccine, 11, 1124, 1993.
414. Barme, M., Stabilizing agents for live viruses for preparing vaccine, and stabilized vaccines containing said agents, U.S. Patent 4,500,512, 1985.
415. Lopes, O. S., Guimarães, S. S. D. A., and Carvalho, R., Studies on yellow fever vaccine, II. Stability of the reconstituted product, J. Biol. Stand., 16, 71, 1988.
416. Finter, N. B., Ferris, R., Kelly, A., and Prydie, J., Effects of adverse storage on live virus vaccines, Dev. Biol. Stand., 41, 271, 1978.
417. Lugosi, L., Stabilité de la viabilité du vaccin BCG sec (souche Pasteur 1173-P2) stocké a 4°C pendant 540 jours: Étude statistique, Ann. Microbiol., 133B, 475, 1982.
418. Wright, D., Muggleton, P. W., and Griffiths, M. I., Evaluation of the stability of dried BCG vaccine, Tubercle, 53, 92, 1972.
419. Lugosi, L., Mulitple comparison of dried BCG vaccines: Stability at 37°C and persistence of strains in the mouse spleen, Vaccine, 2, 149, 1984.
420. Bunch-Christensen, K., The thermostability of different BCG products, WHO/TB/81, 118, 1, 1981.
421. Janaszek, W., Badanie czynniköw warunkujacych stabilinosc szczepionki BCG, Med. Dosw. Mikrobiol., 44, 137, 1992.
422. Sirks, J. L., Cohen, H., and Smith, L., Production of freeze-dried BCG-vaccine, Symp. Ser. Immunobiol. Stand., 17, 163, 1971.
423. Ungar, J. and Stanic, M., The effect of DMSO on BCG freeze-dried vaccine, Symp. Ser. Immunobiol. Stand., 17, 179, 1971.
424. Stavri, D, Stavri, H., and Draghici, D., Selection of a BCG population with increased freeze-drying resistance, Dev. Biol. Stand., 58, 139, 1986.
425. Freudenstein, H., Long-term stability of BCG vaccine sealed in ampoules under nitrogen with reference to its short-term heat resistance, Dev. Biol. Stand., 58, 133, 1986.
426. Chouchkova, M., and Engibarov, A., Studies of the biological activity of two strains of BCG: Influence of production conditions, Dev. Biol. Stand., 58, 105, 1986.
427. Gheorghiu, M., Lagrange, P. H., Lagranderie, M., and Balazuc, A. M., The effects of dispersed or surface grown cultures, manufacture, and control methods on BCG standardization, Dev. Biol. Stand., 58, 191, 1986.
428. Gheorghiu, M., Lagrange, P. H., and Fillastre, C., The stability and immunogenicity of a dispersed-grown freeze-dried Pasteur BCG vaccine, J. Biol. Stand., 16, 15, 1988.
429. Sumpaico, J. S. and Sumpaico, I. W., The stability of liquid BCG vaccine, J. Philipp. Med. Assoc., 43, 289, 1967.
430. Balazs, D., Pitur, I., Draghici, D., and Tasca, G., Stability of the Romanian dried BCG vaccine in different conditions of storage, Dev. Biol. Stand., 58, 173, 1986.
431. van Ramhorst, J. D. and Wezel, A. L., The stability of the components of quadruple (DPT-Polio) vaccines, in Proceedings of Symposium on Stability and Effectiveness of Measles, Poliomyelitis, and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
432. Ikic, D., Higy-Mandic, L. J., Sesardic-Canadjija, I., and Vidakovic-Bival, V., Testing of stability of freeze-dried and fluid pertussis vaccines in Proceedings of Symposium, on Stability and Effectiveness of Measles, Poliomyelitis, and Pertussis Vaccines, D. Ikic, Ed., Zagreb: Yugoslav Academy of Sciences and Arts, 1976.
433. Olson, B. H., Eldering, G., and Graham, B., Stabilization of pertussis vaccine in the presence of benzethonium chloride, J. Bacteriol., 87, 543, 1964.
434. Clarke, P. D. and Forrest, B. D., Medical preparations, WO Patent 93/11220, 1993.
435. Cryz, S. J., Jr., Pasteris, O., Varallyay, S. J., and Fürer, E., Factors influencing the stability of live oral attenuated bacterial vaccines, Dev. Biol. Stand., 87, 277, 1996.
436. Damjanovic, V., Kinetics of thermal death and prediction of the stabilities of freeze-dried streptomycin-dependent live Shigella vaccines, J. Biol. Stand., 2, 297, 1974.